Heron Therapeutics Inc (HRTX) 13F Holders & Ownership Data (165 Funds, Q2 2026)

HRTX ranks #3466 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

165 institutions disclose a position in HRTX, but none treat it as a major bet — even Velan Capital Investment Management LP, its most concentrated holder, allocates just 2.3% of its own portfolio to it.

Cliff Asness has added to its HRTX position for two straight quarters, increasing it by $174.0K to reach $663.2K today.

Rubric Capital Management LP has trimmed its HRTX position for two straight quarters, cutting it by $26.2M while still holding $12.8M.

HRTX is down 3.1% today, and institutions have been net sellers of $1.3M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

HRTX reported a net loss of $20.2M in its latest fiscal year.

• Not yet profitable — net loss of $20.2M in the latest fiscal year
• Revenue grew 7.4% year over year
• Net income declined year over year, from -$13.6M to -$20.2M
• Operating cash flow was negative, using $27.6M in cash
• Current ratio of 2.48x — enough short-term assets to cover short-term liabilities
• Liabilities run 16.85x equity — a highly leveraged balance sheet worth noting